Casey LynchCEO at Cortexyme
Casey Lynch is Co-Founder and CEO of Cortexyme, Inc.a clinical stage company developing a novel potential therapeutics for Alzheimer’s and other degenerative diseases. Previously, Ms. Lynch was the Co-founder and Managing Partner of NeuroInsights, an investment advisory firm focused on neuropharmceuticals and neurodevices. She was also the Co-founder, President and the Chief Executive Officer of Aspira Biosystems, Inc, a proteomics company. Prior to four years building Aspira B, Ms. Lynch oversaw toxicology screening and evaluated new product opportunities at Centaur Pharmaceuticals, where she managed animal screening protocols for a novel nitrone small molecule library. She has a scientific background in disease research, drug discovery, and cell biology. Ms. Lynch conducted preclinical testing for Alzheimer’s disease treatment at the Wadsworth Medical Center and researched the neurological basis of schizophrenia and epilepsy at UCLA. Her graduate work on neurotrophic factor cell biology and neurodegenerative diseases was carried out in Mobley lab at UCSF and Stanford University. Ms. Lynch holds a B.S. in Neuroscience from UCLA and an M.S. in Neuroscience from U.C.S.F. She has also completed the Management Development for Entrepreneurs (MDE) program of the Anderson School of Business.